Related Articles
Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer
Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer
Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer
A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel
Effect of dutasteride on castration‑resistant prostate cancer